ClinicalTrials.gg
RecruitingNCT07245069AlpacaUpdated Nov 24, 2025

Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients

A Phase 2 interventional study of Dapagliflozin 10 mg and Placebo in Heart Failure, Anthracycline-induced Cardiac Toxicity and Endothelial Function (FMD), sponsored by University Medical Centre Ljubljana. Recruiting at 1 site in Slovenia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by University Medical Centre Ljubljana · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Feb 2025, registered Nov 2025).
  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies testing dapagliflozin in Heart Failure — 15 open to participants now, 19 under way, 6 of them phase 3. dapagliflozin · Heart Failure.

Planned enrollment
28th of 59
100 · median 100
Started
2025
with 4 others
Phase 2
9 of 59
4 open now
Primary completion
2028-11
later than 15 of 18 live
Registered
56th of 59
by date

Among the 59 studies testing dapagliflozin in Heart Failure, this one is the 28th largest by planned enrollment, is one of 5 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 15 of the 18 other live ones, and was the 56th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

15 of the 59 studies testing dapagliflozin in Heart Failure are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing dapagliflozin in Heart Failure, or all of them as a file.
02

Study summary

The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused by anthracycline chemotherapy in adult women with breast cancer receiving (neo)adjuvant treatment.

The main questions the study aims to answer are:

i) Does dapagliflozin reduce the decline in left ventricular function (measured by LVEF, GLS, and myocardial work) during and after anthracycline therapy? ii) Does dapagliflozin lessen the deteriorating effect of chemotherapy on endothelial function and arterial stiffness? iii) Does dapagliflozin effect levels of cardiac injury and inflammation biomarkers (e.g., hs-troponin T, NT-proBNP, ST-2, GDF-15, galectin-3, IL-6, MPO)?

Researchers will compare dapagliflozin 10 mg daily with placebo to see whether those receiving dapagliflozin experience less heart and vascular impairment during treatment.

Participants will:

  • Take either dapagliflozin or placebo once daily during anthracycline chemotherapy.
  • Undergo heart and vascular ultrasound, and a 6-minute walk test before chemotherapy and again at 24 and 52 weeks.
  • Provide blood samples before, during and after chemotherapy to measure cardiac biomarkers.
  • Complete multiple questionnaires on quality of life.
Read the detailed description

Anthracycline-based chemotherapy remains a cornerstone of (neo)adjuvant treatment for breast cancer but is limited by a well-recognized risk of cardiotoxicity. This injury may manifest as left ventricular systolic dysfunction, abnormalities in myocardial deformation, impaired myocardial work efficiency, endothelial dysfunction, or increased arterial stiffness. Changes often occur early during treatment and may progress to clinically significant heart failure months or years after completion of chemotherapy. Current preventive strategies focus primarily on strict control of cardiovascular risk factors, as no pharmacologic intervention has consistently demonstrated efficacy in preventing anthracycline-induced cardiotoxicity.

SGLT-2 inhibitors, including dapagliflozin, have demonstrated robust cardiovascular benefits across diverse populations, independent of diabetes status. Clinical trials in heart failure and mechanistic studies indicate that SGLT-2 inhibition favorably affects myocardial energetics, reduces oxidative stress and inflammation, improves endothelial function, and modulates myocardial remodeling. Retrospective observational data in patients exposed to anthracyclines suggest fewer cardiac events among individuals using SGLT-2 inhibitors, but no prospective randomized trial has evaluated this potential cardioprotective effect.

This randomized, double-blind, placebo-controlled clinical trial is designed to determine whether dapagliflozin can attenuate cardiac and vascular deterioration associated with anthracycline chemotherapy in adults with breast cancer. Approximately 100 participants scheduled to receive four cycles of anthracycline-based (neo)adjuvant chemotherapy will be randomized (1:1) to receive dapagliflozin 10 mg once daily or matching placebo. Treatment will begin prior to or at the initiation of chemotherapy and continue according to protocol-defined duration.

Baseline evaluation includes transthoracic echocardiography with quantification of left ventricular ejection fraction (LVEF, using the modified biplane Simpson method), global longitudinal strain (GLS, via speckle-tracking in three apical views), and myocardial work indices derived from noninvasive blood pressure and strain analysis. Vascular ultrasonography will assess endothelial function through brachial artery flow-mediated dilation (FMD) and arterial stiffness via carotid pulse wave velocity (PWV) and stiffness index β. Functional capacity will be measured using the 6-minute walk test. Participants will also provide blood samples for a comprehensive biomarker panel including markers of myocardial injury (high-sensitivity troponin), hemodynamic stress (NT-proBNP), myocardial remodeling (ST-2, GDF-15, galectin-3), and inflammation (IL-6, myeloperoxidase). Quality of life will be assessed using EQ-5D, KCCQ, and SF-36 questionnaires.

All assessments (cardiac imaging, vascular studies, functional testing, and biomarker sampling) will be repeated at 24 and 52 weeks following initiation of chemotherapy, with an additional biomarker time point after two chemotherapy cycles and at the end of anthracycline treatment. This protocol enables characterization of both acute and subacute trajectories of myocardial and vascular injury.

The primary objective is to determine whether dapagliflozin reduces the degree of anthracycline-related left ventricular dysfunction, particularly reflected in GLS and myocardial work indices. Secondary objectives include evaluating effects on LVEF, endothelial function (FMD), arterial stiffness (PWV, stiffness β), biomarker profiles, functional capacity, and patient-reported outcomes. Safety monitoring will include systematic assessment of adverse events related to dapagliflozin, such as genitourinary infections, volume depletion, hypotension, and rare ketoacidosis. All participants will be monitored according to predefined stopping criteria and standard clinical safety procedures.

By integrating advanced cardiac and vascular phenotyping with serial biomarker profiling, this study aims to generate high-quality evidence on whether dapagliflozin provides meaningful primary prevention of anthracycline-induced cardiotoxicity. If beneficial, this approach could inform future cardio-oncology guidelines and improve cardiovascular safety for patients undergoing anthracycline chemotherapy.

03

Conditions studied

  • Heart Failure
  • Anthracycline-induced Cardiac Toxicity
  • Endothelial Function (FMD)
  • Arterial Stiffness
  • Breast Cancer

Keywords

  • Anthracycline-induced cardiac toxicity
  • Dapagliflozin
  • Breast Cancer
  • Cardio-Oncology
  • Primary Prevention
  • Global Longitudinal Strain
  • Myocardial Work
  • Endothelial Function
  • Flow-Mediated Dilation
  • Pulse Wave Velocity
  • Troponin
  • NT-proBNP
  • Heart Failure
  • Inflammation
  • Sodium-Glucose Transporter 2 Inhibitors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults ≥18 years.
  • confirmed breast cancer with planned (neo) anthracycline-based chemotherapy (4 cycles of epirubicin + cyclophosphamide or doxorubicin + cyclophosphamide).
  • Eligible to start dapagliflozin or placebo prior to or at initiation of chemotherapy.
  • Able to perform baseline echocardiography, vascular ultrasound (FMD and carotid stiffness), 6-minute walk test, and biomarker sampling.
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Known heart failure (any prior diagnosis of HF).
  • valvular heart disease.
  • Prior exposure to chemotherapy or radiotherapy to the left chest.
  • Type 1 diabetes mellitus.
  • Symptomatic hypotension.
  • History of recurrent urinary tract infections.
  • History of diabetic ketoacidosis or ketonemia.
  • Severe hepatic impairment (, AST, ALP >3× ).
  • Severe renal impairment ( \<20 mL/min/1.73 m²).
  • Known allergy or intolerance to SGLT-2 inhibitors.
  • Any use of SGLT-2 inhibitor therapy within 3 months prior to enrollment.
  • Pregnancy or breastfeeding.
  • Any condition that, in the investigator's judgment, could interfere with study participation, safety, or completion.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dapagliflozin 10 mg Daily

    Participants randomized to this arm will receive dapagliflozin 10 mg orally once daily for a total duration of 52 weeks (1 year). Study medication will begin before or at the start of anthracycline chemotherapy and will continue throughout chemotherapy and the post-treatment follow-up period, according to protocol.

    Drug: Dapagliflozin 10 mg

  • Placebo comparator
    Placebo

    Participants randomized to this arm will receive a matching placebo orally once daily for a total duration of 52 weeks (1 year). Placebo will be initiated before or at the start of anthracycline chemotherapy and continued throughout chemotherapy and the 1-year protocol-defined follow-up period.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Global Longitudinal Strain (GLS)

    Global Longitudinal Strain (GLS), measured using speckle-tracking echocardiography in three apical views, will be used to quantify subclinical left ventricular systolic dysfunction. The primary endpoint is the change in GLS from baseline to 24 and 52 weeks. A relative worsening of \>15% is considered clinically meaningful.

    Time frame: 52 weeks

  2. Change in Flow-Mediated Dilation (FMD) of the Brachial Artery

    Endothelial function will be assessed by ultrasound measurement of flow-mediated dilation (FMD) of the brachial artery after forearm cuff occlusion. The endpoint is the absolute change in FMD (%) from baseline to 24 weeks. A reduction \>2 absolute percentage points will be considered clinically meaningful. FMD will also be measured at 52 weeks to characterize the sustained effect of dapagliflozin on endothelial function compared with placebo.

    Time frame: 52 weeks

Secondary outcomes

  1. Change in Cardiovascular and Inflammatory Biomarkers

    Serum concentrations of high-sensitivity cardiac troponin, NT-proBNP, ST-2, GDF-15, galectin-3, interleukin-6, and myeloperoxidase will be measured at predefined time points. The endpoint is the change in biomarker levels from baseline to 24 weeks, analyzed as absolute and/or relative change. Biomarkers will also be assessed at 52 weeks to evaluate longer-term effects of dapagliflozin on myocardial injury, hemodynamic stress, remodeling, and inflammation compared with placebo.

    Time frame: 52 weeks

  2. Change in Health-Related Quality of Life (EQ-5D Index Score)

    Quality of life will be assessed using the EQ-5D questionnaire (5-dimension index score). The endpoint is the change in EQ-5D index score from baseline to 24 weeks. Higher scores indicate better health status. The questionnaire will also be administered at 52 weeks to evaluate longer-term effects of dapagliflozin versus placebo on patient-reported quality of life.

    Time frame: 52 weeks

  3. Change in Left Ventricular Ejection Fraction (LVEF)

    LVEF will be measured by transthoracic echocardiography using the modified biplane Simpson method from apical 4- and 2-chamber views. The endpoint is the absolute change in LVEF (%) from baseline to 24 weeks. A decrease ≥10 percentage points or a drop below 53% will be considered clinically relevant. LVEF will also be assessed at 52 weeks to evaluate longer-term effects of dapagliflozin versus placebo on left ventricular systolic function.

    Time frame: 52 weeks

  4. Change in Carotid Arterial Stiffness (Pulse Wave Velocity and Stiffness Index β)

    Arterial stiffness will be evaluated by ultrasound-based assessment of carotid pulse wave velocity (PWV) and stiffness index β using dedicated software. The endpoint is the absolute change in carotid PWV (m/s) and stiffness index β from baseline to 24 weeks. An increase in PWV ≥1 m/s will be considered clinically relevant. Measurements will be repeated at 52 weeks to assess persistent vascular effects of dapagliflozin versus placebo.

    Time frame: 52 weeks

  5. KCCQ (Kansas City Cardiomyopathy Questionnaire)

    The KCCQ Overall Summary Score (0-100 scale) evaluates symptoms, physical limitations, social function, and quality of life related to cardiac health. The endpoint is the change in the Overall Summary Score from baseline to 24 weeks. A change ≥5 points is considered clinically meaningful. KCCQ will also be collected at 52 weeks to determine whether dapagliflozin influences patient-perceived cardiac function and symptom burden over time.

    Time frame: 52 weeks

  6. Change in SF-36 Health Survey Physical and Mental Component Summary Scores

    Health-related quality of life will be evaluated using the SF-36 questionnaire, generating Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. The endpoint is the change in PCS and MCS from baseline to 24 weeks. Higher scores reflect better perceived health. SF-36 will also be administered at 52 weeks to assess sustained effects of dapagliflozin on global well-being and functional status.

    Time frame: 52 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Nov 2028, 45 months after the start.

Of 111 non-industry phase 2 interventional studies under Heart Failure, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 66. This study's planned 45 months is above that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 24, 2025
StartActual
Feb 1, 2025
Primary completionEst.
Nov 2028
CompletionEst.
Feb 2029
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07245069
Responsible party
Jure Tršan (MD, University Medical Centre Ljubljana) — Principal investigator
First posted
Nov 24, 2025
Start date
Feb 1, 2025
Primary completion
Nov 2028 (estimated)
Completion
Feb 2029 (estimated)
Last update
Nov 24, 2025

Study contacts

Jure Tršan
Contact
jure.trsan@gmail.com
Slovenia ext. +3861 5228011

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion